Home / Company / Board of Directors

Board of Directors

To help us orient our long-term decisions and strategy, we rely on an experienced and dependable board of seasoned industry professionals, investors and health care specialists:

Shannon A. Fairbanks

Chair of the Fairbanks Investment Fund Holdings LLC, Ms. Fairbanks provides Invectys Inc. with her broad experience, including 25 years in private investment.

David Guyer, M.D.

David Guyer M.D. is President and CEO of EyeBio, which develops a pipeline of clinical and preclinical candidates for the prevention and treatment of vision loss associated with retinal vascular leakage – a known risk factor for retinal diseases. A testament to its success, EyeBio is soon to be acquired by Merck for up to $3 billion, including an upfront payment of $1.3 billion in cash and a further potential $1.7 billion in milestones. Dr. Guyer is also a Venture Partner at SV Health Investors. His leadership and vision have been recognized through several awards including 2003 Ernst & Young Entrepreneur of the Year Award in Life Science.

Maurizio Zanetti, M.D.

A professor of Medicine at the UCSD, Pr. Zanetti is the pioneer of T cell responses to telomerase reverse transcriptase in cancer patients. He is the Director of the Laboratory of Immunology at the UCSD Moores Cancer Center. He brings his vast knowledge to Invectys’ strategic decisions, especially in the domain of T cells.

Jake Kushner, M.D.

Dr. Jake Kushner leads Invectys Inc. as President & CEO, and member of the Board of Directors. Versed in both business and medicine, Jake served as Chief of Pediatric Diabetes and Endocrinology at Baylor College of Medicine and Texas Children’s Hospital, and Medical Director at McNair Interests.